Table 3 Univariate and multivariate analysis of clinical variables and ATP1As for DSS
Characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value | |
FIGO stage (stage I–II vs. stage III–IV) | 2.244 (0.922–5.462) | 0.075 | 1.092 (0.257–4.639) | 0.905 |
Histologic grade (G1–2 vs. G3–4) | 1.313 (0.833–2.07) | 0.24 | ||
Primary therapy outcome (SD-PD vs. PR-CR) | 0.299 (0.201–0.443) | < 0.001 | 0.296 (0.169–0.517) | < 0.001 |
Age (< 60 vs. ≥ 60) | 1.248 (0.944–1.65) | 0.12 | ||
Tumor residual (NRD vs. RD) | 2.559 (1.572–4.166) | < 0.001 | 2.991 (1.526–5.86) | 0.001 |
Lymphatic invasion (no vs. yes) | 1.407 (0.816–2.425) | 0.219 | ||
Venous invasion (no vs. yes) | 0.846 (0.45–1.591) | 0.604 | ||
Anatomic subdivision (unilateral vs. bilateral) | 1.034 (0.747–1.431) | 0.841 | ||
TP53 mutation (no vs. yes) | 0.643 (0.386–1.07) | 0.089 | 1.026 (0.565–1.861) | 0.934 |
BRCA mutation (no vs. yes) | 0.596 (0.313–1.134) | 0.115 | ||
ATP1A1 (low vs. high) | 1.135 (0.857–1.501) | 0.377 | ||
ATP1A2 (low vs. high) | 1.304 (0.984–1.727) | 0.064 | 1.413 (0.958–2.085) | 0.082 |
ATP1A3 (low vs. high) | 1.572 (1.188–2.081) | 0.002 | 1.723 (1.169–2.54) | 0.006 |
ATP1A4 (low vs. high) | 0.721 (0.544–0.956) | 0.023 | 0.611 (0.408–0.916) | 0.017 |